Lexpos News

Negotiations on the Community Pharmacy Contractual Framework (CPCF) arrangements for 2026/27 are still in progress between Community Pharmacy England, the Department of Health and Social Care (DHSC) and NHS England. Whilst all parties have been working hard on the negotiations, it is clear that they will not reach a conclusion before the start of the [...]

The post CPCF 2026/27: Ongoing negotiations mean no immediate changes appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (27/03/2026) confirmed the following list of price concessions for March 2026: Please note: Community Pharmacy England has submitted price concession applications for a number of other medicines affected by pricing issues this month. We will issue further updates as soon as we hear back from the [...]

The post March 2026 Price Concessions 3rd Update appeared first on Community Pharmacy England.

Following representations from Community Pharmacy England, the Department of Health and Social Care (DHSC) has re-determined that the following products will be granted special container status from 1 April 2026. Generic drug name (dm+d descriptor) Brand and/or manufacturer Pack Size Special container Afatinib 20mg tablets Giotrif® 20mg tablets (Boehringer Ingelheim Ltd) 28 tablet        [...]

The post 13 products re-classified as special containers from April 2026 appeared first on Community Pharmacy England.

The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 April 2026. Key g Special container – This product is a special container and should be dispensed in its complete original pack size. n Item requiring reconstitution [...]

The post Drug Tariff Watch – April 2026 appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Apixaban 2.5mg and 5mg tablets (Sandoz Limited) Drug alert number: EL(26)A/17 Date issued: 26 March 2026 Sandoz Ltd. have informed the MHRA that the Patient Information Leaflet included in specified batches of Apixaban does not contain up‑to‑date information. DMRC reference number: DMRC-38614094 Marketing Authorisation Holder: Sandoz Limited Medicine Details Product [...]

The post MHRA Class 4 Medicines Defect Notification: Apixaban 2.5mg and 5mg tablets (Sandoz Limited) appeared first on Community Pharmacy England.